XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
P/E ratio for XBiotech Inc. (XBIT)
P/E ratio as of 2023: -4.94
According to XBiotech Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.94. At the end of 2022 the company had a P/E ratio of -3.25.
P/E ratio history for XBiotech Inc. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -4.94 |
| 2022 | -3.25 |
| 2021 | -19.20 |
| 2020 | -42.99 |
| 2019 | 1.09 |
| 2018 | -8.60 |
| 2017 | -4.15 |
| 2016 | -6.22 |
| 2015 | -8.93 |
| 2014 | -33.94 |
| 2013 | -74.28 |
| 2012 | -48.64 |